| Patient | Gwen Ifill |
|---|---|
| Date of birth | 1965-09-29 |
| Identifiers | MRN HR-ML032-SYN; SSN (made up) 000-32-5814 |
| Document date | 2026-08-11 |
| Author | Lorna Achebe-Price, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. Ifill is a 60-year-old journalist with stage IIIC2 mismatch repair deficient endometrial cancer, treated with surgery and six cycles of dostarlimab, carboplatin and paclitaxel, who comes for her yearly preventive visit six weeks after the end of combination treatment. The CT then showed no evidence of disease. She had her first maintenance dose of dostarlimab six weeks ago and has her second today. Since starting levothyroxine her energy has improved and she no longer feels cold. The tingling in her toes is slowly fading. She has had no vaginal bleeding or discharge, pelvic pain, cough, leg swelling or weight loss. She is working full days again, covering the election campaign, and walks most mornings. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 60 |
| Endometrial cancer | No evidence of disease at the end of treatment; dostarlimab maintenance dose 2 today |
| Thyroid | Levothyroxine for six weeks; energy better |
| Mood | PHQ-2 0 |
Health risk assessment. Completed by the patient on the clinic's online form before the visit and reviewed with her by Dr. Achebe-Price. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and improving |
| Psychosocial | Busy and engaged at work; close friends and church community; low stress apart from the campaign schedule |
| Substance use | No tobacco; alcohol occasionally, within low-risk limits; no drug use |
| Physical activity | Brisk walk of 30 minutes on most mornings |
| Nutrition | Regular meals; trying to eat more vegetables and less takeout on long workdays |
| Sleep | Six to seven hours on work nights |
| Falls and home safety | No falls; numbness in the toes is fading; good lighting at home |
| Sexual health | Not sexually active at present; knows to report vaginal dryness or pain |
| Activities of daily living | Independent |
| Seat belt and smoke alarms | Always wears a seat belt; smoke alarms tested |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever or weight loss |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No diarrhea, abdominal pain or blood in the stool |
| Genitourinary | Negative | No vaginal bleeding or discharge; no urinary symptoms |
| Breast | Negative | No lump or nipple change |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash or itching |
| Neurological | Positive | Faint tingling in the toes, fading |
| Endocrine | Negative | No longer feels cold; no thirst |
| Psychiatric | Negative | Mood good; PHQ-2 0 |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-02-03 to 2026-02-17 | completed | S |
| Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2026-02-24 to 2026-06-30 | completed | S |
| Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years | Every 6 weeks | Intravenous route | 2026-06-30 | active | S |
| Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast | One tablet daily before breakfast | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-11 | Body height | 165 | cm | S |
| 2026-08-11 | Body weight | 73 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 70 | /min | S |
| 2026-08-11 | Respiratory rate | 16 | /min | S |
| 2026-08-11 | Body temperature | 36.6 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-11 | Thyrotropin [Units/volume] in Serum or Plasma | 3.6 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-08-11 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-08-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 2026-08-11 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-11 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=199 mg/dL | High | S |
| 2026-08-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 124 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-08-11 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-08-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 73.0 kg; blood pressure 124/78; pulse 70 |
| Neck | Thyroid not enlarged or tender; no lymph nodes |
| Breasts | Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Port-site scars healed; soft, non-tender; no mass |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Extremities | No leg swelling; calf circumferences equal |
| Skin | No rash or suspicious lesions |
| Neurological | Pinprick slightly reduced over the toes only; vibration and ankle reflexes normal; steady gait |
| Psychiatric | Engaged and direct |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
| Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | C54.1 | S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public. |
| Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2ii | active | confirmed | C77.8 | S — Synthetic nodal disease found at surgical staging. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
| Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2) | active | confirmed | E03.2 | S — Synthetic immune-related adverse event, among the most common with PD-1 inhibitors. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 124/78 mmHg |
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 4 six weeks ago |
| Unhealthy alcohol use screening | Completed today | Occasional use within low-risk limits |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Ordered | Mammogram every two years from 40 to 74; none in the past two years on file; booked in two weeks |
| Cervical cancer screening | Not indicated | Total hysterectomy with removal of the cervix for endometrial cancer; routine vaginal cytology is not recommended for surveillance |
| Colorectal cancer screening | Ordered | No screening on file; the tumor's MLH1 loss is explained by promoter methylation, so average-risk screening applies; stool immunochemical test chosen, with colonoscopy if positive |
| Diabetes and lipid screening | Completed today | A1c 5.5% at intake; total cholesterol 204, LDL 124, HDL 58, triglycerides 110 mg/dL; ten-year risk below the statin threshold |
| HIV and hepatitis C screening | Up to date | Both negative before cancer treatment |
| Osteoporosis screening | Not indicated | Age 60 without a fracture, steroid course or low body weight; bone density at 65 |
| Lung cancer screening | Not indicated | Never smoker |
| Pneumococcal, zoster and Tdap vaccines | Completed today | PCV20, recombinant zoster dose 1 and Tdap given today |
| Influenza and COVID-19 vaccines, this season | Due | This autumn, when the season's vaccines arrive |
| Dental and eye examinations | Due | Dental review and an eye examination advised this year |
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]
Guideline basis: Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018); Colorectal Cancer: Screening (2021); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Age (2026)
Follow-up: Mammogram in two weeks; stool test result by phone. Dostarlimab every six weeks with TSH, free T4, liver tests and glucose. Gynecologic oncology examination every three months and CT every six months. Influenza and COVID-19 vaccines this autumn. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment aimed at cure and control of her cancer, wants to be told plainly what is happening, and wants to make her own decisions. She named a health care agent, recorded in the confidential part of the chart and not named here, and asked that information about her health be shared only with the people she names. She chose not to record other treatment preferences today. To be revisited yearly or if her illness changes. [S]